PSMA PET | Hear more about a Prostate Cancer Patient’s Journey!
PSMA PET/CT Clinical Utility in Prostate ImagingPET/CT is refining the understanding of prostate cancer and increasing confidence in the initial diagnosis
Delivering on the Promise: Telix Anticipates Demand for 68GA PSMA-11The 68Ga generator manufacturers have been strategically planning for the incremental 68Ga demand.
Going Beyond Traditional Diagnostics and Therapies, Delivering Precise Cancer TreatmentsTheranostics supports the diagnosis and management of cancer patients.
The Promise of Nuclear MedicineDeveloping Cancer Detection and Treatment with Molecularly Targeted Radiation (MTR)
Combination Therapy Improves Efficacy in Widespread Prostate Metastatic Disease
The Use of PSMA Targeted Therapy and Hormone Therapy in Renally Impaired PatientAn 82-year-old man presented with rising PSA of 21 ng/ml in July 2015.
Recurrent Prostate Cancer68 Ga PSMA-11 PET/CT is more likely to change the course of treatment than conventional imaging.
Metastatic Castrate-Resistant Prostate Cancer (mCRPC))A 69-year-old man presented with a persistent rising PSA.
Localized Prostate Cancer RecurrenceA 70-year-old man presented with persistent rising PSA.
© Anderson Publishing, Ltd. 2024 All rights reserved. Reproduction in whole or part without express written permission Is strictly prohibited.